|Bid||0.00 x 800|
|Ask||0.00 x 1000|
|Day's Range||20.76 - 21.70|
|52 Week Range||13.42 - 30.90|
|Beta (5Y Monthly)||2.86|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 09, 2021 - Aug 13, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||36.20|
The biotech sector was in focus last week with pipeline and regulatory updates from Moderna (MRNA) and Alkermes (ALKS), among others.
BASEL, Switzerland, June 01, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, invites investors and the general public to listen to webcasts at the following investor conferences: Goldman Sachs 42nd Annual Global Healthcare Virtual Conference on June 8, 2021 at 4:40 p.m. Eastern Time. Company management will participate in a fireside chat.JMP Securities Life Sciences Conference on June 17, 2021 at 10:00 a.m. Eastern Time. Company management will participate in a fireside chat. The presentations will be accessible on the Events page under the Investors & Media section of the Myovant website at www.myovant.com. About Myovant Sciences Myovant Sciences aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. Founded in 2016, we have two FDA-approved products. ORGOVYX™ (relugolix) was approved by the U.S. Food and Drug Administration in 2020 as the first and only oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer, and relugolix is also under regulatory review in Europe for men with advanced prostate cancer. MYFEMBREE® (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) was approved in the U.S. in 2021 as the first once-daily treatment for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women. Relugolix combination tablet (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) is under regulatory review in Europe for women with uterine fibroids, has completed Phase 3 registration-enabling studies for women with endometriosis, and is being assessed for contraceptive efficacy in healthy women ages 18-35 years who are at risk for pregnancy. We are also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, which has completed a Phase 2a study for female infertility as part of assisted reproduction. Sumitovant Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is our majority shareholder. For more information, please visit our website at www.myovant.com. Follow @Myovant on Twitter and LinkedIn. Investor Contact:Ryan CroweVice President, Investor RelationsMyovant Sciences, Inc.+1 (650) firstname.lastname@example.org Media Contact:Albert Liao Director, Corporate CommunicationsMyovant Sciences, Inc.+1 (650) email@example.com
The FDA has approved Myovant Sciences Ltd (NYSE: MYOV) and Pfizer Inc’s (NYSE: PFE) relugolix combined with estradiol and norethindrone acetate for heavy menstrual bleeding linked to uterine fibroids in premenopausal women. The once-daily treatment will be marketed as Myfembree, with a treatment duration of up to two years. Wednesday’s approval marks the second FDA nod for Myovant in less than a year after relugolix scored a go-ahead in prostate cancer in December. The company is also testing its flagship drug in women with endometriosis, another painful disorder involving the uterus’ tissue, and pregnancy prevention medication. Pfizer will help Myovant sell Myfembree for uterine fibroid patients in the U.S. as early as June. The FDA based its Myfembree approval on two replicate phase 3 trials, Liberty 1 and Liberty 2, that showed the med significantly beat placebo in preventing blood loss among women with uterine fibroids. Specifically, 72.1% and 71.2% of women in the relugolix arm responded to the treatment compared with 16.8% and 14.7% of women in the placebo groups after 24 weeks, respectively. In its approval, the FDA warned that the drug shouldn’t be used for longer than 24 months due to the risk of continued bone loss that may not be reversible. Price Action: PFE shares are up 0.18% at $38.99, while MYOV shares are down 1.39% at $23.35 during the premarket session on the last check Thursday. Related content: Benzinga's Full FDA Calendar See more from BenzingaClick here for options trades from BenzingaFDA May Not Review New COVID-19 Vaccine Emergency Use RequestsModerna Sees Single-Dose COVID-19 Vaccine Launch In India In 2022© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.